Abstract
BRAF inhibitors (BRAFi) that target BRAF V600E kinase, a driver mutation found in 50% of melanomas, show a significant antitumor response, but the com......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
